SchrÖDinger今日公开宣布，已与Tectora Therapeutics签署一项许可与合作协议。Tectora Therapeutics是由SchrÖDinger共同创立的全新生物技术企业，其核心使命在于推进免疫学与炎症领域的研究项目。此次合作象征着两家公司在科学探索道路上的深度携手，意在将前沿技术转化为突破性疗法，为患者带来新的希望。
SchrÖDinger今日公开宣布，已与Tectora Therapeutics签署一项许可与合作协议。Tectora Therapeutics是由SchrÖDinger共同创立的全新生物技术企业，其核心使命在于推进免疫学与炎症领域的研究项目。此次合作象征着两家公司在科学探索道路上的深度携手，意在将前沿技术转化为突破性疗法，为患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.